biotech · Huntington’s Disease · Amyotrophic Lateral Sclerosis (ALS)
iQure Pharma
uniQure biopharma B.V.
uniQure biopharma is a biotech organization headquartered in EU. Primary therapeutic focus areas include Huntington’s Disease, Amyotrophic Lateral Sclerosis (ALS). NovaPharmaNews links 2 clinical program(s), 0 drug profi
Princeton, USA HQ
2019 Founded
9 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Princeton, USA
- Founded
- 2019
- Employees
- 9
- Programs
- 2
- Drugs
- 2
- Patents
- 0
AMT-162-001
Phase 2 · other · Amyotrophic Lateral Sclerosis (ALS)
AMT-162-001 for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (other) at uniQure biopharma B.V. with 1 ClinicalTrials.gov record(s).
Internal code AMT-162-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- uniQure biopharma B.V.
- Phase
- Phase 2
- Modality
- other
- Indication
- Amyotrophic Lateral Sclerosis (ALS)
- Status
- active
- Trials
- 1